Abstract 1745P
Background
Approximately 30-40% will develop distant metastasis and will eventually succumb to the disease. Beyond first-line, disease control is modest, with median progression-free survival (PFS) ranging 2.6–4.6 months The value of trabectedin (T) has been emphasized beyond the first line in the treatment of metastatic soft tissue sarcomas. There are data of T + Radiotherapy (RT) in combination,30Gy in 10 sessions.
Methods
Retrospective review of patients' medical records who have received trabectedin in the last 5 years. Descriptive analysis has been conducted. In a subsequent step, progression-free survival (PFS) and overall survival (OS) were analyzed. A specific analysis was conducted on the subgroup that received a combination with RT.
Results
We analyzed 207 patients, with a predominance of women 116 (56%) and 91 men. 73 pts get treatment at second line (2L), and 75 pts get trabectedin in third line (3L). PFS in all patients is around 6 months influence due to time patients get treatment. PFS in pts treated at 2L 14 month, 6 month as 3L, and lower in subsequences lines. P=0,001. OS (43m vs 41) p=no significance. Leiomyosarcoma (Lei) and liposarcoma (Lipo) exhibit the best PFS compared to the others, with statistical significance. A lesser response to trabectedin was observed in those presenting with metastatic disease at onset (PFS 6m (M1) vs 9 (M0)) There was no objective worsening in PFS for patients who experienced dose reduction or delayed administration. 80 pts were treated with RT, most patients were Lei (24), Lipo (20), synovial sarcoma (8), UPS (7), pleomorphic rhabdomyosarcoma (5) and stromal sarcoma (3). PFS in those receiving concurrent RT(9m) versus those who did not (5m) p=0,086. Disease control rate in irradiated lesion was 89%, with a better response in Lei and synovial sarcomas.
Conclusions
All patients treated showed benefit with PFS 6 month, higher than literature review. There are significant differences with a higher PFS in patient with lower number of previous lines. There are various factors that influence the response, such as metastatic presentation, metastasis location, histological subtype, and RT. RT provides adequate disease control, with improvement in the survival of these patients.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1740P - Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial
Presenter: Yuhong Zhou
Session: Poster session 06
1741P - Ethically-sensitive clinical scenarios in adult patients with sarcomas: A real-world single-institution survey and a classification attempt
Presenter: Paolo G. Casali
Session: Poster session 06
1742P - Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study
Presenter: Pau Mascaró Baselga
Session: Poster session 06
1743P - A phase II study of fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma
Presenter: Zhiguo Luo
Session: Poster session 06
1746P - Real-world characterization of patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) in Japan in MASTER KEY project
Presenter: Kenji Tsuchihashi
Session: Poster session 06
1747P - Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study
Presenter: Evelyne Roets
Session: Poster session 06
1748P - A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)
Presenter: Xi Guo
Session: Poster session 06
1749P - Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified?
Presenter: Tania Moussa
Session: Poster session 06
1750P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Gale Rizzae Mercado Alcala
Session: Poster session 06
1751P - Clinical and survival data of 336 myxoid liposarcoma patients: The Gustave Roussy experience
Presenter: Tarek Assi
Session: Poster session 06